Royalty Pharma PLC (RPRX)
25.80
+0.10
(+0.37%)
USD |
NASDAQ |
Nov 18, 16:00
25.80
0.00 (0.00%)
After-Hours: 20:00
Royalty Pharma Enterprise Value: 20.65B for Nov. 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 15, 2024 | 20.65B |
| November 14, 2024 | 20.60B |
| November 13, 2024 | 20.72B |
| November 12, 2024 | 20.78B |
| November 11, 2024 | 20.94B |
| November 08, 2024 | 20.88B |
| November 07, 2024 | 21.01B |
| November 06, 2024 | 21.07B |
| November 05, 2024 | 21.47B |
| November 04, 2024 | 21.32B |
| November 01, 2024 | 21.27B |
| October 31, 2024 | 21.27B |
| October 30, 2024 | 21.36B |
| October 29, 2024 | 21.34B |
| October 28, 2024 | 21.39B |
| October 25, 2024 | 21.25B |
| October 24, 2024 | 21.40B |
| October 23, 2024 | 21.44B |
| October 22, 2024 | 21.44B |
| October 21, 2024 | 21.61B |
| October 18, 2024 | 21.71B |
| October 17, 2024 | 21.74B |
| October 16, 2024 | 21.82B |
| October 15, 2024 | 21.65B |
| October 14, 2024 | 21.66B |
| Date | Value |
|---|---|
| October 11, 2024 | 21.73B |
| October 10, 2024 | 21.49B |
| October 09, 2024 | 21.53B |
| October 08, 2024 | 21.44B |
| October 07, 2024 | 21.53B |
| October 04, 2024 | 21.61B |
| October 03, 2024 | 21.61B |
| October 02, 2024 | 21.83B |
| October 01, 2024 | 21.89B |
| September 30, 2024 | 21.85B |
| September 27, 2024 | 20.97B |
| September 26, 2024 | 20.96B |
| September 25, 2024 | 20.72B |
| September 24, 2024 | 20.74B |
| September 23, 2024 | 20.74B |
| September 20, 2024 | 20.67B |
| September 19, 2024 | 20.87B |
| September 18, 2024 | 20.97B |
| September 17, 2024 | 20.98B |
| September 16, 2024 | 20.99B |
| September 13, 2024 | 20.75B |
| September 12, 2024 | 20.67B |
| September 11, 2024 | 20.77B |
| September 10, 2024 | 20.90B |
| September 09, 2024 | 20.92B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
19.54B
Minimum
Sep 21 2023
28.75B
Maximum
Jan 26 2021
23.98B
Average
24.48B
Median
Oct 12 2021
Enterprise Value Benchmarks
| Geron Corp | 1.957B |
| Amicus Therapeutics Inc | 3.032B |
| Ionis Pharmaceuticals Inc | 4.217B |
| Arbutus Biopharma Corp | 561.96M |
| Syndax Pharmaceuticals Inc | 944.82M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 543.99M |
| Revenue (Quarterly) | 564.69M |
| Total Expenses (Quarterly) | -170.38M |
| EPS Diluted (Quarterly) | 1.21 |
| Profit Margin (Quarterly) | 96.33% |
| Earnings Yield | 9.89% |
| Operating Earnings Yield | 10.04% |
| Normalized Earnings Yield | 7.597 |